| 10.52 1.23 (13.24%) | 11-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.92  |
1-year : | 21.68 |
| Resists | First : | 14.49 |
Second : | 18.56 |
| Pivot price | 9.49 |
|||
| Supports | First : | 7.9 | Second : | 6.57 |
| MAs | MA(5) : | 9.09  |
MA(20) : | 9.88 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -1.6 |
Signal : | -1.8 |
| %K %D | K(14,3) : | 29.4 |
D(3) : | 18 |
| RSI | RSI(14): 45.6 |
|||
| 52-week | High : | 25 | Low : | 5.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ YDES ] has closed below upper band by 24.6%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 11.28 - 11.32 | 11.32 - 11.36 |
| Low: | 9.21 - 9.26 | 9.26 - 9.3 |
| Close: | 10.44 - 10.51 | 10.51 - 10.57 |
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.
Mon, 24 Nov 2025
YD Bio Limited - Ordinary Shares (Nasdaq:YDES) Stock Quote - Markets Financial Content
Mon, 01 Sep 2025
YD Bio Limited Announces Closing of Business Combination - citybiz
Fri, 29 Aug 2025
Cancer Detection Biotech YD Bio Debuts on Nasdaq: DNA Methylation Pioneer Raises $11.5M for Expansion - Stock Titan
Thu, 28 Aug 2025
Cancer Detection Biotech YD Bio Goes Public: $11.5M SPAC Deal Powers DNA Methylation Technology - Stock Titan
Fri, 15 Aug 2025
Taiwan Biotech YD Biopharma Secures Path to Nasdaq Through Breeze Holdings SPAC Merger Approval - Stock Titan
Fri, 15 Aug 2025
Breeze Holdings Acquisition Corp. Shareholders Approve Business Combination with YD Biopharma Limited - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 153 (K) |
| EPS | -0.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.57 |
| Profit Margin | -276.6 % |
| Operating Margin | -444.6 % |
| Return on Assets (ttm) | -25.5 % |
| Return on Equity (ttm) | -42.7 % |
| Qtrly Rev. Growth | 95.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -526.01 |
| PEG Ratio | 0 |
| Price to Book value | 2.3 |
| Price to Sales | 1453.62 |
| Price to Cash Flow | -403.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|